<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00320216</url>
  </required_header>
  <id_info>
    <org_study_id>CR005416</org_study_id>
    <secondary_id>C0379T04</secondary_id>
    <nct_id>NCT00320216</nct_id>
    <nct_alias>NCT00322998</nct_alias>
  </id_info>
  <brief_title>A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis</brief_title>
  <official_title>A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study of Single and Multiple Dose Regimens With Subcutaneous CNTO 1275 (Human Monoclonal Antibody to IL-12) in Subjects With Moderate to Severe Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centocor, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of initial single and
      multiple subcutaneous injections of CNTO 1275 in the treatment of patients with moderate to
      severe plaque psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (the study medication is assigned by chance), double blind (neither
      physician nor patient knows the treatment that the patient receives), parallel-group,
      multicenter study to determine the effectiveness and safety of two different doses of CNTO
      1275 administered subcutaneously one time or as multiple doses as compared with placebo in
      patients with moderate to severe plaque-type psoriasis (the most common type of psoriasis).
      The dose of CNTO 1275 will be 45 or 90 mg administered subcutaneously once or as four weekly
      doses. Patients who inadequately respond to their treatment may receive one additional dose.
      Patients will be monitored for the safety throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75% Improvement at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Psoriasis Area and Severity Index (PASI)(0 [ best] -72 [worst]) score at Week 12. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved Physician's Global Assessment (PGA) Score of Clear (1) or Excellent (2) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Number of participants achieving a physician global assessment (PGA)(1 [best] to 6 [worst]) score of clear or excellent at Week 12. The PGA is used to determine the participants psoriasis lesions overall at a given time point. Overall lesions will be graded for induration, erythema, and scaling. The sum of the 3 scales will be divided by 3 to obtain a final PGA score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved Psoriasis Area Severity Index (PASI) 75% Improvement at Week 32</measure>
    <time_frame>Week 32</time_frame>
    <description>Psoriasis Area and Severity Index (PASI)(0 [ best] -72 [worst]) score at Week 32 for participants who were not retreated at Week 16. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved Psoriasis Area Severity Index (PASI) 75% Improvement (0-72) at Week 28</measure>
    <time_frame>Week 28</time_frame>
    <description>Psoriasis Area and Severity Index (PASI)(0 [ best] -72 [worst]) score at Week 28 for participants who were retreated at Week 16. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Group I (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the placebo group will receive placebo at Weeks 0, 1, 2, 3, and 16. At week 20, all patients will receive a single dose of ustekinumab 90 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (Ustekinumab 45 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive single dose ustekinumab at Week 0 and placebo at Weeks 1, 2, and 3. At Week 16, patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 45 mg. At week 20, all patients will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III (Ustekinumab 90 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 90 mg single dose ustekinumab at Week 0 and placebo at Weeks 1, 2, and 3. At Week 16 patients with PGA greater than or equal to 3 will receive ustekinumab 90 mg. At week 20, all patients will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 45 mg of ustekinumab at Weeks 0, 1, 2, and 3. At Week 16, patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 45 mg. At week 20, all patients will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 90 mg of ustekinumab at Weeks 0, 1, 2, and 3. At Week 16 patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 90 mg. At week 20, all patients will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
    <description>Patients will receive subcutaneous injections of ustekinumab (45 or 90 mg).</description>
    <arm_group_label>Group II (Ustekinumab 45 mg)</arm_group_label>
    <arm_group_label>Group III (Ustekinumab 90 mg)</arm_group_label>
    <arm_group_label>Group IV</arm_group_label>
    <arm_group_label>Group V</arm_group_label>
    <other_name>CNTO 1275</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients in the placebo group will receive placebo medication.</description>
    <arm_group_label>Group I (Placebo)</arm_group_label>
    <arm_group_label>Group II (Ustekinumab 45 mg)</arm_group_label>
    <arm_group_label>Group III (Ustekinumab 90 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have had a diagnosis of plaque-type psoriasis at least 6 months

          -  Plaque-type psoriasis covering at least 10% of total body surface areas

          -  Psoriasis area-and-severity index score of 12 or greater

          -  Considered by treating dermatologist to be a candidate for phototherapy or systemic
             treatment of psoriasis

          -  Women of childbearing potential and all men must agree to use adequate birth control
             measures

          -  Have no history of latent or active tuberculosis

        Exclusion Criteria:

          -  Currently have nonplaque forms of psoriasis or drug-induced psoriasis

          -  Women who are pregnant or nursing, or men and women planning pregnancy while enrolled
             in the study

          -  Patients who have a history of chronic or recurrent infectious disease or who have or
             have had a serious infection requiring hospitalization or intravenous antibiotics
             within the previous 2 months

          -  Patients who have or ever have had a nontuberculous mycobacterial infection or
             opportunistic infection

          -  Patients known to be infected with human immunodeficiency virus, hepatitis B, or
             hepatitis C

          -  Patients who have current signs or symptoms of severe, progressive, or uncontrolled
             renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac,
             neurologic, cerebral, or psychiatric disease

          -  Have any known malignancy or have a history of malignancy within the previous 5 years
             (with the exception of basal cell carcinoma of the skin that has been treated with no
             evidence of recurrence)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Centocor, Inc. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Centocor, Inc.</affiliation>
  </overall_official>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2006</study_first_submitted>
  <study_first_submitted_qc>April 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2006</study_first_posted>
  <results_first_submitted>October 23, 2009</results_first_submitted>
  <results_first_submitted_qc>November 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2012</results_first_posted>
  <last_update_submitted>March 31, 2015</last_update_submitted>
  <last_update_submitted_qc>March 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>CNTO 1275</keyword>
  <keyword>Ustekinumab</keyword>
  <keyword>Stelara</keyword>
  <keyword>Interleukin-12</keyword>
  <keyword>IL-12</keyword>
  <keyword>Interleukin-23</keyword>
  <keyword>IL-23</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>320 participants from 45 sites in North America were randomized to receive either Ustekinumab or placebo.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo (CP)</title>
          <description>Controlled period (Week 0-20) - receiving placebo at Weeks 0, 1, 2, 3 and 16.</description>
        </group>
        <group group_id="P2">
          <title>Ustekinumab 45 mg (CP)</title>
          <description>Controlled period (Week 0-20) - receiving ustekinumab 45 mg at Weeks 0. At week 16, participants with PGA &gt;= 3 received ustekinumab 45 mg.</description>
        </group>
        <group group_id="P3">
          <title>Ustekinumab 90 mg (CP)</title>
          <description>Controlled period (Week 0-20) - receiving ustekinumab 90 mg at Weeks 0. At week 16, participants with PGA &gt;= 3 received ustekinumab 90 mg.</description>
        </group>
        <group group_id="P4">
          <title>Ustekinumab 45 mg Weekly for 4 Weeks (CP)</title>
          <description>Controlled period (Week 0-20) - receiving ustekinumab 45 mg at Weeks 0, 1, 2 and 3. At week 16, participants with PGA &gt;= 3 received ustekinumab 45 mg.</description>
        </group>
        <group group_id="P5">
          <title>Ustekinumab 90 mg Weekly for 4 Weeks (CP)</title>
          <description>Controlled period (Week 0-20) - receiving ustekinumab 90 mg at Weeks 0, 1, 2 and 3. At week 16, participants with PGA &gt;= 3 received ustekinumab 90 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="64">1 patient randomized but not treated was included as discontinued due to Other reason.</participants>
                <participants group_id="P3" count="64">1 patient randomized but not treated was included as discontinued due to Other reason.</participants>
                <participants group_id="P4" count="64"/>
                <participants group_id="P5" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="58"/>
                <participants group_id="P4" count="61"/>
                <participants group_id="P5" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group I: Placebo</title>
          <description>Participants received placebo at Weeks 0, 1, 2 and 3. At week 16, all participants received placebo regardless of Physician's Global Assessment (PGA). At week 20, all participants received a single dose of ustekinumab 90 mg.</description>
        </group>
        <group group_id="B2">
          <title>Group II: Ustekinumab 45 mg</title>
          <description>Participants received ustekinumab 45 mg at Week 0 followed by placebo at Weeks 1, 2 and 3. At week 16, participants who had a Physician's Global Assessment (PGA) &gt;=3 received 45 mg ustekinumab and participants with a PGA&lt;3 received placebo. At week 20, all participants received placebo.</description>
        </group>
        <group group_id="B3">
          <title>Group III: Ustekinumab 90 mg</title>
          <description>Participants received ustekinumab 90 mg at Week 0 followed by placebo at Weeks 1, 2 and 3. At week 16, participants who had a Physician's Global Assessment (PGA) &gt;=3 received 90 mg ustekinumab and participants with a PGA&lt;3 received placebo. At week 20, all participants received placebo.</description>
        </group>
        <group group_id="B4">
          <title>Group IV: Ustekinumab 45 mg Weekly for 4 Weeks</title>
          <description>Participants received ustekinumab 45 mg at Weeks 0, 1, 2 and 3. At week 16, participants who had a Physician's Global Assessment (PGA) &gt;=3 received 45 mg ustekinumab and participants with a PGA&lt;3 received placebo. At week 20, all participants received placebo.</description>
        </group>
        <group group_id="B5">
          <title>Group V: Ustekinumab 90 mg Weekly for 4 Weeks</title>
          <description>Participants received ustekinumab 90 mg at Weeks 0, 1, 2 and 3. At week 16, participants who had a Physician's Global Assessment (PGA) &gt;=3 received 90 mg ustekinumab and participants with a PGA&lt;3 received placebo. At week 20, all participants received placebo.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
            <count group_id="B2" value="64"/>
            <count group_id="B3" value="64"/>
            <count group_id="B4" value="64"/>
            <count group_id="B5" value="64"/>
            <count group_id="B6" value="320"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.0" spread="13.7"/>
                    <measurement group_id="B2" value="46.4" spread="14.2"/>
                    <measurement group_id="B3" value="45.5" spread="12.7"/>
                    <measurement group_id="B4" value="44.5" spread="12.2"/>
                    <measurement group_id="B5" value="44.3" spread="13.3"/>
                    <measurement group_id="B6" value="44.9" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75% Improvement at Week 12</title>
        <description>Psoriasis Area and Severity Index (PASI)(0 [ best] -72 [worst]) score at Week 12. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score.</description>
        <time_frame>Week 12</time_frame>
        <population>Intent to treat. All participants randomized were included in the analysis according to the assigned treatment groups. Participant is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I: Placebo</title>
            <description>Participants received placebo at Weeks 0, 1, 2 and 3. At week 16, all participants received placebo regardless of Physician's Global Assessment (PGA). At week 20, all participants received a single dose of ustekinumab 90 mg.</description>
          </group>
          <group group_id="O2">
            <title>Group II: Ustekinumab 45 mg</title>
            <description>Participants received ustekinumab 45 mg at Week 0 followed by placebo at Weeks 1, 2 and 3. At week 16, participants who had a Physician's Global Assessment (PGA) &gt;=3 received 45 mg ustekinumab and participants with a PGA&lt;3 received placebo. At week 20, all participants received placebo.</description>
          </group>
          <group group_id="O3">
            <title>Group III: Ustekinumab 90 mg</title>
            <description>Participants received ustekinumab 90 mg at Week 0 followed by placebo at Weeks 1, 2 and 3. At week 16, participants who had a Physician's Global Assessment (PGA) &gt;=3 received 90 mg ustekinumab and participants with a PGA&lt;3 received placebo. At week 20, all participants received placebo.</description>
          </group>
          <group group_id="O4">
            <title>Group IV: Ustekinumab 45 mg Weekly for 4 Weeks</title>
            <description>Participants received ustekinumab 45 mg at Weeks 0, 1, 2 and 3. At week 16, participants who had a Physician's Global Assessment (PGA) &gt;=3 received 45 mg ustekinumab and participants with a PGA&lt;3 received placebo. At week 20, all participants received placebo.</description>
          </group>
          <group group_id="O5">
            <title>Group V: Ustekinumab 90 mg Weekly for 4 Weeks</title>
            <description>Participants received ustekinumab 90 mg at Weeks 0, 1, 2 and 3. At week 16, participants who had a Physician's Global Assessment (PGA) &gt;=3 received 90 mg ustekinumab and participants with a PGA&lt;3 received placebo. At week 20, all participants received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75% Improvement at Week 12</title>
          <description>Psoriasis Area and Severity Index (PASI)(0 [ best] -72 [worst]) score at Week 12. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score.</description>
          <population>Intent to treat. All participants randomized were included in the analysis according to the assigned treatment groups. Participant is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="43"/>
                    <measurement group_id="O5" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel chi square test</method>
            <method_desc>Stratified by baseline weight [&lt;=90kg vs &gt; 90 kg].</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>Stratified by baseline weight [≤ 90kg vs &gt; 90 kg)].</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>Stratified by baseline weight [≤ 90kg vs &gt; 90 kg)].</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis:No difference between any ustekinumab group and placebo at an overall significant level of 0.05. Sample Size: With 300 participants (60 in each treatment group), simulation studies were conducted to calculate the power to detect a treatment difference in primary endpoint between ustekinumab groups and placebo using a CMH test with stratification by baseline weight [≤ 90kg vs &gt; 90 kg). For all the scenarios evaluated, the power is &gt;99% at an overall significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>To control for the multiplicity for the primary endpoint analysis, the 4 pairwise comparisons between ustekinumab groups and placebo were performed sequentially at alpha = 0.05. The order of testing was prespecified from high to low doses.</p_value_desc>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>Stratified by baseline weight [≤ 90kg vs &gt; 90 kg)].</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved Physician's Global Assessment (PGA) Score of Clear (1) or Excellent (2) at Week 12</title>
        <description>Number of participants achieving a physician global assessment (PGA)(1 [best] to 6 [worst]) score of clear or excellent at Week 12. The PGA is used to determine the participants psoriasis lesions overall at a given time point. Overall lesions will be graded for induration, erythema, and scaling. The sum of the 3 scales will be divided by 3 to obtain a final PGA score.</description>
        <time_frame>Week 12</time_frame>
        <population>Participants were included in the analysis according to the assigned treatment groups. Participant is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy. Other missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I: Placebo</title>
            <description>Participants received placebo at Weeks 0, 1, 2 and 3. At week 16, all participants received placebo regardless of Physician's Global Assessment (PGA). At week 20, all participants received a single dose of ustekinumab 90 mg.</description>
          </group>
          <group group_id="O2">
            <title>Group II: Ustekinumab 45 mg</title>
            <description>Participants received ustekinumab 45 mg at Week 0 followed by placebo at Weeks 1, 2 and 3. At week 16, participants who had a Physician's Global Assessment (PGA) &gt;=3 received 45 mg ustekinumab and participants with a PGA&lt;3 received placebo. At week 20, all participants received placebo.</description>
          </group>
          <group group_id="O3">
            <title>Group III: Ustekinumab 90 mg</title>
            <description>Participants received ustekinumab 90 mg at Week 0 followed by placebo at Weeks 1, 2 and 3. At week 16, participants who had a Physician's Global Assessment (PGA) &gt;=3 received 90 mg ustekinumab and participants with a PGA&lt;3 received placebo. At week 20, all participants received placebo.</description>
          </group>
          <group group_id="O4">
            <title>Group IV: Ustekinumab 45 mg Weekly for 4 Weeks</title>
            <description>Participants received ustekinumab 45 mg at Weeks 0, 1, 2 and 3. At week 16, participants who had a Physician's Global Assessment (PGA) &gt;=3 received 45 mg ustekinumab and participants with a PGA&lt;3 received placebo. At week 20, all participants received placebo.</description>
          </group>
          <group group_id="O5">
            <title>Group V: Ustekinumab 90 mg Weekly for 4 Weeks</title>
            <description>Participants received ustekinumab 90 mg at Weeks 0, 1, 2 and 3. At week 16, participants who had a Physician's Global Assessment (PGA) &gt;=3 received 90 mg ustekinumab and participants with a PGA&lt;3 received placebo. At week 20, all participants received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved Physician's Global Assessment (PGA) Score of Clear (1) or Excellent (2) at Week 12</title>
          <description>Number of participants achieving a physician global assessment (PGA)(1 [best] to 6 [worst]) score of clear or excellent at Week 12. The PGA is used to determine the participants psoriasis lesions overall at a given time point. Overall lesions will be graded for induration, erythema, and scaling. The sum of the 3 scales will be divided by 3 to obtain a final PGA score.</description>
          <population>Participants were included in the analysis according to the assigned treatment groups. Participant is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy. Other missing data were not imputed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>Stratified by baseline weight [≤ 90kg vs &gt; 90 kg)].</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>Stratified by baseline weight [≤ 90kg vs &gt; 90 kg)].</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: No difference between any ustekinumab group and placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel (CMH) chi square</method>
            <method_desc>Stratified by baseline weight [≤ 90kg vs &gt; 90 kg)].</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved Psoriasis Area Severity Index (PASI) 75% Improvement at Week 32</title>
        <description>Psoriasis Area and Severity Index (PASI)(0 [ best] -72 [worst]) score at Week 32 for participants who were not retreated at Week 16. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score.</description>
        <time_frame>Week 32</time_frame>
        <population>Participants were included in the analysis according to the assigned treatment groups. Participant is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy. Other missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I: Placebo</title>
            <description>Participants received placebo at Weeks 0, 1, 2 and 3. At week 16, all participants received placebo regardless of Physician's Global Assessment (PGA). At week 20, all participants received a single dose of ustekinumab 90 mg.</description>
          </group>
          <group group_id="O2">
            <title>Group II: Ustekinumab 45 mg</title>
            <description>Participants received ustekinumab 45 mg at Week 0 followed by placebo at Weeks 1, 2 and 3. At week 16, participants who had a Physician's Global Assessment (PGA) &gt;=3 received 45 mg ustekinumab and participants with a PGA&lt;3 received placebo. At week 20, all participants received placebo.</description>
          </group>
          <group group_id="O3">
            <title>Group III: Ustekinumab 90 mg</title>
            <description>Participants received ustekinumab 90 mg at Week 0 followed by placebo at Weeks 1, 2 and 3. At week 16, participants who had a Physician's Global Assessment (PGA) &gt;=3 received 90 mg ustekinumab and participants with a PGA&lt;3 received placebo. At week 20, all participants received placebo.</description>
          </group>
          <group group_id="O4">
            <title>Group IV: Ustekinumab 45 mg Weekly for 4 Weeks</title>
            <description>Participants received ustekinumab 45 mg at Weeks 0, 1, 2 and 3. At week 16, participants who had a Physician's Global Assessment (PGA) &gt;=3 received 45 mg ustekinumab and participants with a PGA&lt;3 received placebo. At week 20, all participants received placebo.</description>
          </group>
          <group group_id="O5">
            <title>Group V: Ustekinumab 90 mg Weekly for 4 Weeks</title>
            <description>Participants received ustekinumab 90 mg at Weeks 0, 1, 2 and 3. At week 16, participants who had a Physician's Global Assessment (PGA) &gt;=3 received 90 mg ustekinumab and participants with a PGA&lt;3 received placebo. At week 20, all participants received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved Psoriasis Area Severity Index (PASI) 75% Improvement at Week 32</title>
          <description>Psoriasis Area and Severity Index (PASI)(0 [ best] -72 [worst]) score at Week 32 for participants who were not retreated at Week 16. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score.</description>
          <population>Participants were included in the analysis according to the assigned treatment groups. Participant is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy. Other missing data were not imputed.</population>
          <units>Particpants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved Psoriasis Area Severity Index (PASI) 75% Improvement (0-72) at Week 28</title>
        <description>Psoriasis Area and Severity Index (PASI)(0 [ best] -72 [worst]) score at Week 28 for participants who were retreated at Week 16. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score.</description>
        <time_frame>Week 28</time_frame>
        <population>Participants were included in the analysis according to the assigned treatment groups. Participant is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy. Other missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group I: Placebo</title>
            <description>Participants received placebo at Weeks 0, 1, 2 and 3. At week 16, all participants received placebo regardless of Physician's Global Assessment (PGA). At week 20, all participants received a single dose of ustekinumab 90 mg.</description>
          </group>
          <group group_id="O2">
            <title>Group II: Ustekinumab 45 mg</title>
            <description>Participants received ustekinumab 45 mg at Week 0 followed by placebo at Weeks 1, 2 and 3. At week 16, participants who had a Physician's Global Assessment (PGA) &gt;=3 received 45 mg ustekinumab and participants with a PGA&lt;3 received placebo. At week 20, all participants received placebo.</description>
          </group>
          <group group_id="O3">
            <title>Group III: Ustekinumab 90 mg</title>
            <description>Participants received ustekinumab 90 mg at Week 0 followed by placebo at Weeks 1, 2 and 3. At week 16, participants who had a Physician's Global Assessment (PGA) &gt;=3 received 90 mg ustekinumab and participants with a PGA&lt;3 received placebo. At week 20, all participants received placebo.</description>
          </group>
          <group group_id="O4">
            <title>Group IV: Ustekinumab 45 mg Weekly for 4 Weeks</title>
            <description>Participants received ustekinumab 45 mg at Weeks 0, 1, 2 and 3. At week 16, participants who had a Physician's Global Assessment (PGA) &gt;=3 received 45 mg ustekinumab and participants with a PGA&lt;3 received placebo. At week 20, all participants received placebo.</description>
          </group>
          <group group_id="O5">
            <title>Group V: Ustekinumab 90 mg Weekly for 4 Weeks</title>
            <description>Participants received ustekinumab 90 mg at Weeks 0, 1, 2 and 3. At week 16, participants who had a Physician's Global Assessment (PGA) &gt;=3 received 90 mg ustekinumab and participants with a PGA&lt;3 received placebo. At week 20, all participants received placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved Psoriasis Area Severity Index (PASI) 75% Improvement (0-72) at Week 28</title>
          <description>Psoriasis Area and Severity Index (PASI)(0 [ best] -72 [worst]) score at Week 28 for participants who were retreated at Week 16. This is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score.</description>
          <population>Participants were included in the analysis according to the assigned treatment groups. Participant is considered a non- responder if the participant has used any pre-specified prohibited medications or discontinued due to lack of efficacy. Other missing data were not imputed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Week 36</time_frame>
      <desc>Three participants received placebo by mistake at Week 0, including 1 participant who was not randomized into the study and 2 participants who were randomized to a CNTO 1275 group but received the incorrect study agent. 1 participant not randomized but treated with placebo was included in the placebo group for adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (CP)</title>
          <description>Controlled period (Week 0-20) - receiving placebo at Weeks 0, 1, 2, 3 and 16.</description>
        </group>
        <group group_id="E2">
          <title>Ustekinumab 45 mg (CP)</title>
          <description>Controlled period (Week 0-20) - receiving ustekinumab 45 mg at Weeks 0. At week 16, participants with PGA &gt;= 3 received ustekinumab 45 mg.</description>
        </group>
        <group group_id="E3">
          <title>Ustekinumab 90 mg (CP)</title>
          <description>Controlled period (Week 0-20) - receiving ustekinumab 90 mg at Weeks 0. At week 16, participants with PGA &gt;= 3 received ustekinumab 90 mg.</description>
        </group>
        <group group_id="E4">
          <title>Ustekinumab 45 mg Weekly for 4 Weeks (CP)</title>
          <description>Controlled period (Week 0-20) - receiving ustekinumab 45 mg at Weeks 0, 1, 2 and 3. At week 16, participants with PGA &gt;= 3 received ustekinumab 45 mg.</description>
        </group>
        <group group_id="E5">
          <title>Ustekinumab 90 mg Weekly for 4 Weeks (CP)</title>
          <description>Controlled period (Week 0-20) - receiving ustekinumab 90 mg at Weeks 0, 1, 2 and 3. At week 16, participants with PGA &gt;= 3 received ustekinumab 90 mg.</description>
        </group>
        <group group_id="E6">
          <title>Placebo -&gt; Ustekinumab 90 mg (After CP)</title>
          <description>After Controlled period (Week 20-36) - receiving placebo at Weeks 0, 1, 2, 3 and 16 -&gt; receiving ustekinumab 90 mg at Week 20.</description>
        </group>
        <group group_id="E7">
          <title>Ustekinumab 45 mg (After CP)</title>
          <description>After Controlled period (Week 20-36) - receiving ustekinumab 45 mg at Week 0. At Week 16, participants with PGA &gt;= 3 received ustekinumab 45 mg.</description>
        </group>
        <group group_id="E8">
          <title>Ustekinumab 90 mg (After CP)</title>
          <description>After Controlled period (Week 20-36) - receiving ustekinumab 90 mg at Week 0. At Week 16, participants with PGA &gt;= 3 received ustekinumab 90 mg.</description>
        </group>
        <group group_id="E9">
          <title>Ustekinumab 45 mg Weekly for 4 Weeks (After CP)</title>
          <description>After Controlled period (Week 20-36) - receiving ustekinumab 45 mg at Weeks 0, 1, 2 and 3. At Week 16, participants with PGA &gt;= 3 received ustekinumab 45 mg.</description>
        </group>
        <group group_id="E10">
          <title>Ustekinumab 90 mg Weekly for 4 Weeks (After CP)</title>
          <description>After Controlled period (Week 20-36) - receiving ustekinumab 90 mg at Weeks 0, 1, 2 and 3. At Week 16, participants with PGA &gt;= 3 received ustekinumab 90 mg.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>WHOART</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hernia congenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine fibroid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Psoriasis aggravated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>WHOART</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="21" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="17" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Arthritis aggravated</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Upper resp tract infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="62"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Generally, the only disclosure restriction on the PI is that the sponsor has 60 days to review results communications prior to public release and can embargo communications regarding trial results for a period that does not exceed 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The count of patients with any nonserious adverse events (NAE) excludes patients who only had NAE that occurred in &lt;=5% of patients. This information may vary from existing approved labeling and publications due to the requirement of this website.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Director Clinical Research</name_or_title>
      <organization>Centocor Research &amp; Development, Inc.</organization>
      <phone>1-800-457-6399</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

